# Weiss Ratings

Type: Company

Source: GetYourBrief — https://getyourbrief.com/entity/weiss-ratings
Canonical HTML page: https://getyourbrief.com/entity/weiss-ratings

## Timeline

- **2026-09-01**: Dividend payment — The $0.36 quarterly dividend is paid to shareholders of record as of August 17.
- **2026-08-23**: Wall Street Zen upgrades both stocks to Hold — Wall Street Zen upgraded CTNM and ENVB from Sell to Hold in Sunday research notes.
- **2026-08-22**: Wall Street Zen issues opposing ratings — Downgraded T1 Energy from Sell to Strong Sell and upgraded SM Energy from Buy to Strong Buy.
- **2026-08-17**: Ex-dividend date — Middlesex Water's quarterly dividend of $0.36 goes ex-dividend.
- **2026-08-16**: Wall Street Zen upgrades both stocks — Wall Street Zen raised AMPY from strong sell to hold and BRSP from sell to hold.
- **2026-08-15**: Wall Street Zen upgrades BKKT and DEI — Wall Street Zen upgraded Bakkt and Douglas Emmett from sell to hold in research notes issued Saturday morning.
- **2026-08-15**: Wall Street Zen upgrades BKKT and DEI — Wall Street Zen upgraded Bakkt and Douglas Emmett from sell to hold in research notes issued Saturday morning.
- **2026-08-14**: Silexion reports quarterly results — Silexion reported a $5.17 loss per share, beating consensus estimates by $16.03; shares fell to $0.42.
- **2026-08-14**: Quarterly earnings release — Lantern Pharma reported quarterly EPS of ($0.57), missing consensus by $0.19; shares rose $0.02 to $2.65.
- **2026-08-14**: Friday trading close — AMPY opened at $4.78 and BRSP opened at $5.00.
- **2026-08-14**: Enveric reports quarterly loss — Enveric Biosciences reported EPS of -$0.76 for the quarter.
- **2026-08-13**: Q2 earnings released; EPS beats consensus — Company reported ($1.40) EPS versus ($1.55) consensus; shares rose $0.05 to $0.57 on 2.3x average volume
- **2026-08-12**: Benchmark cuts BKKT target — Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
- **2026-08-12**: Benchmark cuts BKKT target — Benchmark reduced its Bakkt price target from $19.00 to $12.00 while maintaining a buy rating.
- **2026-08-12**: T1 Energy earnings and BTIG target move — T1 Energy reported a -$0.09 EPS loss; BTIG raised its T1 target from $8.00 to $9.00 with a Buy rating.

## Recent coverage (20 stories, network-wide)

### Hold Upgrades for CTNM and ENVB: $20.25 Target vs $1.43 Microcap
2026-08-24 11:32:31 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A Sunday analyst action shifted two healthcare microcaps from Sell to Hold. CTNM carries a $646.69M valuation and a $20.25 consensus target, while ENVB trades at $1.43 with a $6.41M market cap and negative P/E.
Full story: https://getfinancebrief.com/story/wall-street-zen-ctnm-envb-hold-upgrades-finance

### Wall Street Zen Upgrades 2 Biotechs: CTNM at $17.19, ENVB at $1.43
2026-08-24 11:32:21 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A rare double upgrade by Wall Street Zen moved Contineum Therapeutics and Enveric Biosciences from Sell to Hold, offering a momentary reprieve for two money-losing clinical-stage biotechs. CTNM trades near its 52-week high at $17.19 with a $20.25 consensus target, while ENVB's psychedelic pipeline carries a $6.41M market cap against a former $17.64 high.
Full story: https://getbiobrief.com/story/wall-street-zen-upgrades-two-biotechs-ctnm-envb-hold-bio

### T1 Energy Cut to Strong Sell at $4.45; SM Energy Upgraded to Strong Buy
2026-08-24 03:19:53 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen issued divergent ratings on two energy names, cutting T1 Energy to Strong Sell while lifting SM Energy to Strong Buy. T1 trades at $4.45 with negative P/E and 3.5 D/E, while SM offers a 7.35 P/E and 0.85 D/E. The split highlights a rotation from leveraged loss-makers to cash-flow-positive mid-cap energy.
Full story: https://getfinancebrief.com/story/t1-energy-strong-sell-sm-energy-strong-buy-wall-street-zen-2026-08

### Northwestern Mutual Adds $125.2M in RTX and Cummins Stakes in Q2
2026-08-24 01:15:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

A Q2 13F filing shows Northwestern Mutual Wealth Management initiated a $106.97M RTX position and an $18.25M Cummins stake. Analysts are raising price targets on both names, reinforcing institutional conviction in industrial cyclicals.
Full story: https://getfinancebrief.com/story/northwestern-mutual-125m-rtx-cummins-13f

### NBP & CRMZ Micro-Cap Earnings: $(0.16) vs $(0.04) EPS
2026-08-22 07:00:25 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Two micro-caps reported late-August earnings: biotech I-Mab posted $(0.16) EPS while CreditRiskMonitor posted $(0.04) EPS on $5.17M revenue. Divergent risk profiles—1.47 beta vs 0.22 beta—highlight small-cap earnings dynamics.
Full story: https://getfinancebrief.com/story/imab-creditriskmonitor-microcap-earnings-comparison

### I-Mab Posts $(0.16) EPS; $9 PT Implies 371% Upside
2026-08-22 07:00:16 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

I-Mab, a clinical-stage oncology and immunology biotech, reported a $(0.16) quarterly EPS on Aug 20. With shares at $1.91, H.C. Wainwright's reiterated $9 target implies massive upside, though Weiss remains bearish. Institutional ownership sits at 38.38%.
Full story: https://getbiobrief.com/story/imab-nbp-q3-2026-earnings-biotech-analysis

### Keysight Guides FY26 EPS to $11.46, Stock Falls 5.5% to $341
2026-08-19 01:09:08 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Keysight Technologies beat Q3 estimates and raised full-year EPS guidance to $11.46 on $7.1 billion revenue, yet shares sold off 5.5% on the news. The reaction highlights valuation concerns despite a forward P/E of about 30.
Full story: https://getfinancebrief.com/story/keysight-fy26-eps-guidance-stock-fall

### Applied Digital Falls 8.6% to $28.51 as Analyst Targets Split
2026-08-19 00:18:04 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Applied Digital shares slid 8.6% to $28.51 despite a Moderate Buy consensus and an average target of $68.15. The decline highlights a growing divide between sell-side optimism and trader concerns about negative earnings and elevated leverage.
Full story: https://getfinancebrief.com/story/applied-digital-8-6-percent-drop-august-2026

### Applied Digital Drops 8.6% as AI Datacenter Bets Face $8.3B Test
2026-08-19 00:17:49 · Sector: ai · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Applied Digital's 8.6% drop to $28.51, paired with a 5.1% fall in quantum peer Rigetti, signals cooling sentiment toward AI-adjacent infrastructure stocks after APLD's July earnings miss. High beta and negative EPS are forcing AI investors to reassess execution risk.
Full story: https://getaibrief.com/story/apld-8-6-percent-drop-ai-infrastructure-reckoning

### AMPY Upgraded to Hold: $4.78 Stock, $9 Target, 10.6 P/E
2026-08-18 04:52:49 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen lifted Amplify Energy to Hold from Strong Sell on August 16, with shares at $4.78 and a $9 consensus target. Thin coverage and insider buying make the upgrade a key sentiment shift for a $198 million small-cap energy name.
Full story: https://getfinancebrief.com/story/ampy-wall-street-zen-hold-upgrade-finance

### Bakkt's $341M Market Cap Gets Hold Upgrade; Revenue Misses by 54%
2026-08-17 01:01:48 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Wall Street Zen's sell-to-hold upgrade for Bakkt comes as the stock trades at $7.66 with a $341.53 million market cap. The move follows a 54% revenue miss and a director's $783,000 insider buy, leaving analysts divided on whether this is a bottom or a value trap.
Full story: https://getfinancebrief.com/story/bakkt-hold-upgrade-wall-street-zen-finance

### Bakkt Upgraded to Hold as BKKT Sits 85% Below Its $49.79 High
2026-08-17 01:01:34 · Sector: crypto · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Crypto platform Bakkt's sell-to-hold upgrade masks a brutal year: shares at $7.66 are down 85% from $49.79. A director's insider buy and an extreme beta of 5.91 frame the risk-reward for Web3 investors watching custody and exchange infrastructure.
Full story: https://getcryptobrief.com/story/bakkt-upgrade-hold-85-percent-below-high

### MBRX Down 97% to $0.57 Despite EPS Beat: $22 Target Stale?
2026-08-17 00:56:51 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Moleculin Biotech shares rose 9.6% to $0.57 after a narrower-than-expected Q2 loss, yet the stock remains down roughly 97% from its 12-month high, with analysts' average $22.00 target detached from reality. The real signal for traders is a 2.3x volume surge, a beta of 1.83, and thin 15.52% institutional ownership.
Full story: https://getfinancebrief.com/story/mbrx-down-97-percent-eps-beat-22-target-stale

### Moleculin's $4.06M Market Cap vs ($1.40) EPS: Pipeline Survival?
2026-08-17 00:56:41 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Clinical-stage Moleculin Biotech is now valued at just $4.06 million after a 97% collapse from its 52-week high, raising existential questions about its ability to fund development of therapies for resistant tumors and viral infections. The EPS 'beat' of ($1.40) versus ($1.55) is a paper figure — no revenue, cash balance, or clinical milestone accompanied the report.
Full story: https://getbiobrief.com/story/moleculin-4m-market-cap-eps-loss-pipeline-survival

### Lantern Pharma Misses EPS by $0.19; AI Oncology Stock Sits 44% Below High
2026-08-16 16:15:06 · Sector: health · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's quarterly EPS miss of $0.19 highlights the cash-intensive nature of AI-powered oncology drug discovery. The clinical-stage company has no product revenue, and its stock trades well below moving averages. Healthcare executives should monitor its platform and funding runway rather than quarterly losses.
Full story: https://gethealthbrief.com/story/lantern-pharma-eps-miss-health-ai-oncology

### LTRN Misses EPS by $0.19 Yet Rises 0.8% to $2.65 on 2.3x Volume
2026-08-16 16:14:56 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma missed quarterly EPS estimates by $0.19, but shares rose 0.76% to $2.65 on double average volume. The micro-cap trades below both moving averages with a beta of 2.34 and a Sell consensus. Institutional accumulation is scattered and small.
Full story: https://getfinancebrief.com/story/ltrn-q2-earnings-miss-stock-reaction

### Lantern Pharma Posts $0.57 Loss, Misses Consensus by $0.19; Sell Rating Stands
2026-08-16 16:14:45 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Lantern Pharma's $0.57 quarterly loss missed consensus by $0.19, underscoring clinical-stage risk. The micro-cap oncology company has no product revenue, and analysts maintain a Sell rating. Biotech investors need clarity on cash runway and upcoming trial catalysts.
Full story: https://getbiobrief.com/story/lantern-pharma-clinical-stage-eps-miss

### SLXN Beats EPS by $16.03 Yet Trades at $0.42, Down 99.5% from High
2026-08-16 15:02:07 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion beat consensus by $16.03 with a ($5.17) EPS, yet shares fell to $0.42. With volume at 2x average, a 52-week high of $80, and Hold consensus, the microcap has shed nearly all value.
Full story: https://getfinancebrief.com/story/silexion-finance-earnings-microcap

### SLXN's RNAi Pipeline Faces $0.42 Stock and $5.17 EPS Loss
2026-08-16 15:01:58 · Sector: bio · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Silexion reported a narrower-than-expected loss of $5.17 per share, but analysts downgraded the stock to Hold. Its RNAi LODER candidates remain preclinical or Phase I, and a $0.42 share price may constrain funding for further oncology development.
Full story: https://getbiobrief.com/story/silexion-rnai-pipeline-earnings

### Mill Capital Buys $1.09M Chubb Stake as Analysts Push Targets to $386
2026-08-16 01:05:50 · Sector: finance · Sentiment: Neutral · Impact: 5/10 · Sources: 2

Institutional 13F data shows new accumulation in Chubb as small advisory firms added positions from Q4 2025 through Q2 2026. Analyst targets range from $301 to $386, while insider sales and 83.81% institutional ownership frame a mixed but liquid market for CB.
Full story: https://getfinancebrief.com/story/mill-capital-chubb-13f-finance-2026

---
This page is a machine-readable summary. Sentiment measures the directional read of each development for this entity, not the tone of the reporting; impact weights consequence, not syndication reach. See https://getyourbrief.com/guides/methodology for the full editorial methodology.